Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Exemestane + Ribociclib + STX-478
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Exemestane Aromasin Aromatase Inhibitor 3 Aromasin (exemestane) is an aromatase inhibitor, which prevents the conversion of androgenic precursors to estrogens (NCI Drug Dictionary).
Ribociclib Kisqali LEE011|LEE-011|LEE 011 CDK4/6 Inhibitor 14 Kisqali (ribociclib) is a dual CDK4/6 inhibitor, which may induce cell cycle arrest and reduce proliferation in cancer cells (PMID: 24045179). Kisqali (ribociclib) is FDA-approved in combination with an aromatase inhibitor in women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer, and in combination with Faslodex (fulvestrant) in postmenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (FDA.gov).
STX-478 STX 478|STX478|LY4064809|Tersolisib PIK3CA inhibitor 27 STX-478 inhibits PIK3CA H1047 mutations, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (Cancer Res 2023;83(5 Suppl):Abstract nr P4-07-04).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT07174336 Phase III Letrozole + Palbociclib Fulvestrant + Palbociclib + STX-478 Anastrozole + Palbociclib Fulvestrant + Ribociclib + STX-478 Abemaciclib + Anastrozole + STX-478 Letrozole + Palbociclib + STX-478 Abemaciclib + Exemestane + STX-478 Letrozole + Ribociclib + STX-478 Abemaciclib + Fulvestrant + STX-478 Fulvestrant + Palbociclib Exemestane + Palbociclib Anastrozole + Palbociclib + STX-478 Abemaciclib + Letrozole + STX-478 Anastrozole + Ribociclib + STX-478 Exemestane + Palbociclib + STX-478 Exemestane + Ribociclib + STX-478 A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Recruiting USA | TUR | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG 3
NCT05768139 Phase Ib/II Exemestane + Ribociclib + STX-478 Exemestane + Palbociclib + STX-478 Anastrozole + Ribociclib + STX-478 Anastrozole + Palbociclib + STX-478 Letrozole + Ribociclib + STX-478 Letrozole + Palbociclib + STX-478 Fulvestrant + Ribociclib + STX-478 Fulvestrant + Palbociclib + STX-478 Fulvestrant + STX-478 STX-478 First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (PIKALO-1) Recruiting USA | NLD | ITA | IRL | FRA | ESP | DEU | BEL 1


Additional content available in Icon for CKB-BoostCKB BOOST